{"id":"ruboxistaurin-mesylate","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug selectively inhibits PKC-beta, an enzyme overactivated in hyperglycemic conditions that drives pathological changes in blood vessels. By blocking PKC-beta signaling, ruboxistaurin reduces vascular permeability, inflammation, and abnormal cell growth in the retina and kidney, thereby slowing progression of diabetic retinopathy and nephropathy.","oneSentence":"Ruboxistaurin mesylate is a protein kinase C (PKC) beta inhibitor that reduces vascular permeability and inflammation in diabetic microvascular complications.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:32:47.889Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic macular edema (DME)"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT00044408","phase":"PHASE3","title":"Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2002-07","conditions":"Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":200},{"nctId":"NCT00190970","phase":"PHASE2","title":"The Effect of Ruboxistaurin on Small Fiber Function","status":"COMPLETED","sponsor":"Chromaderm, Inc.","startDate":"2004-10","conditions":"Diabetic Neuropathy","enrollment":52},{"nctId":"NCT00044395","phase":"PHASE3","title":"Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-07","conditions":"Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent","enrollment":200},{"nctId":"NCT00044421","phase":"PHASE3","title":"Treatment of Peripheral Neuropathy in Patients With Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-07","conditions":"Diabetic Neuropathies, Diabetes Mellitus","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ruboxistaurin mesylate","genericName":"Ruboxistaurin mesylate","companyName":"Chromaderm, Inc.","companyId":"chromaderm-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ruboxistaurin mesylate is a protein kinase C (PKC) beta inhibitor that reduces vascular permeability and inflammation in diabetic microvascular complications. Used for Diabetic macular edema (DME), Diabetic retinopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}